TXG
10x Genomics, Inc. · Healthcare · Medical - Healthcare Information Services
Señales de momentum (gestores comparables):
amplitud de titulares +7.1% ·
flujo de acciones +1.4% ·
nuevas posiciones netas +6.7%
· fórmula
Acumulación amplia: acciones en aumento entre más titulares
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q4 2024
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 153.99K | $11.76M | n/a | n/a |
| Q2 2026 | 113 | +6 | 98.93M | $3.79B | +15 | −8 |
| Q1 2026 | 109 | +3 | 94.02M | $1.99B | +12 | −10 |
| Q4 2025 | 107 | +3 | 97.86M | $1.59B | +4 | n/a |
| Q3 2025 | 19 | -2 | 71.88M | $839.83M | n/a | −3 |
| Q2 2025 | 19 | +1 | 64.66M | $748.72M | +2 | −1 |
| Q1 2025 | 15 | 0 | 30.56M | $266.82M | +1 | −1 |
| Q4 2024 | 15 | +1 | 24.83M | $356.61M | +3 | −2 |
| Q3 2024 | 13 | 0 | 22.71M | $512.82M | +1 | −1 |
| Q2 2024 | 13 | n/a | 21.07M | $409.76M | n/a | n/a |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | ARK Investment Management ✦ | 11.94M | +11.1% | $171.52M | 1.4% | ▲ Add | 3 | SEC ↗ |
| 2 | Citadel Advisors ✦ | 2.01M | -27.8% | $28.81M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 3 | Geode Capital Management ✦ (pasivo) | 1.81M | -0.1% | $26.07M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 4 | T. Rowe Price ✦ | 1.78M | -29.2% | $25.58M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 5 | State Street Global Advisors ✦ (pasivo) | 1.77M | n/a | $25.49M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Two Sigma Investments ✦ | 1.32M | +291.2% | $18.95M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | D. E. Shaw & Co. ✦ | 1.22M | Nuevo | $17.50M | 0.0% | New | 1 | SEC ↗ ×2 |
| 8 | Millennium Management ✦ | 991.16K | +7.9% | $14.23M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 9 | Capital World Investors ✦ | 793.30K | 0.0% | $11.39M | 0.0% | Held | 3 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 517.20K | -29.1% | $7.43M | 0.0% | ▼ Trim | 3 | SEC ↗ ×4 |
| 11 | Renaissance Technologies ✦ | 386.95K | Nuevo | $5.56M | 0.0% | New | 1 | SEC ↗ |
| 12 | PRIMECAP Management ✦ | 127.60K | -56.8% | $1.83M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 13 | Norges Bank ✦ (pasivo) | 91.58K | +123.0% | $1.32M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 14 | Marshall Wace ✦ | 46.86K | -90.0% | $672,924 | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 15 | Gotham Asset Management ✦ | 18.39K | Nuevo | $264,066 | 0.0% | New | 1 | SEC ↗ |
"Their weight" = la participación de la posición en el valor de renta variable 13F reportado por ese manager: la medida de convicción. ✦ = manager curado.
Nuevos compradores
| D. E. Shaw & Co. | $17.50M | 0.0% |
| Renaissance Technologies | $5.56M | 0.0% |
| Gotham Asset Management | $264,066 | 0.0% |
Posición cerrada
| Point72 Asset Management | $27.78M | era 0.1% |
| Baillie Gifford | $911,736 | era 0.0% |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 328 tenedores, 124.40M acciones, $2.59B declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué más suelen tener los titulares rastreados de este valor: recuentos de titularidad compartida, no relaciones fundamentales.
Compras en mercado abierto (P)
Sin compras en mercado abierto por parte de insiders en nuestra ventana de cobertura.
Ventas en mercado abierto (S)
Officer, Director · 1.00K acc. · $78,228
Director · 1.22K acc. · $100,542
Director · 2.27K acc. · $185,391
Director · 1.32K acc. · $107,082
Director · 614 acc. · $48,820
Director · 292 acc. · $22,833
Officer, Director · 2.80K acc. · $230,622
Officer, Director · 9.90K acc. · $810,071
Officer, Director · 9.30K acc. · $752,401
Officer, Director · 2.00K acc. · $159,239
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología